Many CNS disorders involve inflammation and microglial activation, and KCa3.1 blockers or knockdown have improved the outcome in animal models of trauma, spinal cord injury, ischemic stroke, multiple sclerosis, and Alzheimer’s disease [reviewed in Ref. The gene discussed is KCNN4; the disease is central nervous system disorder.